Search

Displaying results 5661 - 5670 of 8697 in total
  1. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  3. Drug

    Aloglutamol

    go.drugbank.com/drugs/DB13650
    Investigational

    Aloglutamol is an antacid salt of aluminium, gluconic acid, and tris. Proprietary names include Altris, Pyreses, Tasto and Sabro.

    Categories: Drugs for Acid Related Disorders
  4. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    [L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574] … [A32574] It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide.

  6. Drug

    Nicaraven

    go.drugbank.com/drugs/DB06397
    Experimental

  7. Drug

    Technetium Tc-99m ciprofloxacin

    go.drugbank.com/drugs/DB05488
    Experimental

    99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  10. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

    Categories: Experimental Unapproved Treatments for COVID-19